Novo Nordisk

Latest news

• 
  Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals (opens in a new tab)

  Stocktwits · Oct 3, 2026

• 
  Novo Nordisk Holds Its 2026 Outlook As FDA Review Of Its Blood Disorder Drug Runs Long (opens in a new tab)

  Stocktwits · Oct 2, 2026

• 
  Anthropic Is Spending $100M To Build The AI Workforce It Needs For Its Next Phase (opens in a new tab)

  Stocktwits · Oct 2, 2026

• 
  Novo provides update on the denecimig Biologics License Application (BLA) in the US (opens in a new tab)

  GlobeNewswire · Oct 2, 2026

• 
  Novo Nordisk Strikes Nearly $4 Billion in 2 Deals. Here's What That Means for Investors (opens in a new tab)

  Motley Fool · Oct 2, 2026

• 
  Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? (opens in a new tab)

  Motley Fool · Oct 2, 2026

• 
  DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care (opens in a new tab)

  Zacks · Oct 2, 2026

• 
  Agios' Growth Story Hinges on Mitapivat's Commercial Expansion (opens in a new tab)

  Zacks · Oct 2, 2026

• 
  Prediction: Eli Lilly Could Be the Next $2 Trillion Drugmaker (opens in a new tab)

  24/7 Wall St. · Oct 2, 2026

• 
  3 drug targets pharma is betting on next (opens in a new tab)

  Pharma Voice · Oct 2, 2026

• 
  LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies (opens in a new tab)

  Zacks · Oct 2, 2026

• 
  How Eli Lilly Just Extended Its Lead in the Weight-Loss Drug Market (opens in a new tab)

  Barrons.com · Oct 1, 2026

• Novo's Wegovy Pill Shows Weight Loss After Switching From Injections (opens in a new tab)

  Oct 1, 2026

• Eli Lilly obesity drug data adds pressure on Novo Nordisk (opens in a new tab)

  Oct 1, 2026

• Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win (opens in a new tab)

  Oct 1, 2026

• Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026 (opens in a new tab)

  Oct 1, 2026

• Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy (opens in a new tab)

  Sep 30, 2026

• Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock. (opens in a new tab)

  Sep 30, 2026

• Novo inngår milliardsamarbeid med svenske Nanexa (opens in a new tab)

  MEDWATCH.no · Sep 25, 2026

• Novo inngår milliardavtale om svensk teknologi (opens in a new tab)

  Dagens Medisin · Sep 25, 2026

• Novo kan bli møtt med millionkrav (opens in a new tab)

  Finansavisen · Sep 25, 2026

• Novo Nordisk inngår milliardavtale med Nanexa (opens in a new tab)

  Finansavisen · Sep 24, 2026

• Novo åpner for USA-notering (opens in a new tab)

  Finansavisen · Sep 23, 2026

• Novo Nordisk-sjef vurderer M&A og pilledrevet fremtid etter investorreaksjon (opens in a new tab)

  Invezz · Sep 22, 2026

• Novo Nordisk vil utvide – aksjen faller (opens in a new tab)

  Dagens Medisin · Sep 22, 2026

• Novo-sjefen: – Da mister man tillit veldig raskt (opens in a new tab)

  Finansavisen · Sep 22, 2026

• Novo-aksjen faller 6 %: plan for nye blockbuster-legemidler og $23B-mål skuffer (opens in a new tab)

  Invezz · Sep 21, 2026

• Novo skuffer investorene – aksjen faller kraftig (opens in a new tab)

  Finansavisen · Sep 21, 2026

• Novo Nordisk-aksjen stuper (opens in a new tab)

  E24 · Sep 21, 2026

• DNB Carnegies anbefaling på Novo Nordisk (opens in a new tab)

  DNB · Sep 21, 2026